Cassava Sciences (SAVA) 10-Q 6 Aug 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 24, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'PTIE	'
Entity Registrant Name	'PAIN THERAPEUTICS INC	'
Entity Central Index Key	'0001069530	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	45,756,117

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$44,575	$48,588	[1]
Marketable securities	250	1,250	[1]
Other current assets	482	265	[1]
Total current assets	45,307	50,103	[1]
Property and equipment, net	72	'
Other assets	12	'
Total assets	45,391	50,103	[1]
Current liabilities:	'	'
Accounts payable	360	445	[1]
Accrued development expense	332	641	[1]
Accrued compensation and benefits	1,047	712	[1]
Other current liabilities	'	3	[1]
Total current liabilities	1,739	1,801	[1]
Noncurrent liabilities	'	'	[1]
Total liabilities	1,739	1,801	[1]
Commitments and contingencies	'	'	[1]
Stockholders' equity:	'	'
Preferred stock	'	'	[1]
Common stock	45	45	[1]
Additional paid-in-capital	154,409	152,363	[1]
Accumulated other comprehensive income	'	1	[1]
Accumulated deficit	-110,802	-104,107	[1]
Total stockholders' equity	43,652	48,302	[1]
Total liabilities and stockholders' equity	$45,391	$50,103	[1]
[1]	Derived from the Company’s audited financial statements as of December 31, 2013, included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Condensed_Statements_Of_Operat

Condensed Statements Of Operations (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenue:	'	'	'	'
Program fee revenue	'	$1,959	'	$3,917
Total revenue	'	1,959	'	3,917
Operating expenses:	'	'	'	'
Research and development	1,935	1,139	4,081	2,322
General and administrative	1,322	1,139	2,639	2,357
Total operating expenses	3,257	2,278	6,720	4,679
Operating loss	-3,257	-319	-6,720	-762
Interest income	11	18	25	53
Net loss	($3,246)	($301)	($6,695)	($709)
Net loss per share, basic and diluted	($0.07)	($0.01)	($0.15)	($0.02)
Weighted-average shares used in computing net loss per share, basic and diluted	45,247	44,999	45,187	44,966

Condensed_Statements_Of_Compre

Condensed Statements Of Comprehensive Loss (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Condensed Statements Of Comprehensive Loss [Abstract]	'	'	'	'
Net loss	($3,246)	($301)	($6,695)	($709)
Other comprehensive gains (losses):	'	'	'	'
Net unrealized gains (losses) on marketable securities	-1	'	-1	3
Comprehensive loss	($3,247)	($301)	($6,696)	($706)

Condensed_Statements_Of_Cash_F

Condensed Statements Of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014		Jun. 30, 2013
Cash flows used in operating activities:	'		'
Net loss	($6,695)		($709)
Adjustments to reconcile net loss to net cash used in operating activities:	'		'
Deferred program fee revenue	'		-3,917
Non-cash stock based compensation	1,667		1,491
Depreciation and amortization	7		'
Non-cash net interest income	-2		-8
Changes in operating assets and liabilities:	'		'
Other current assets	-217		250
Other assets	-12		'
Accounts payable	-85		74
Accrued development expense	-309		-357
Accrued compensation and benefits	335		-474
Other accrued liabilities	-3		-24
Net cash used in operating activities	-5,314		-3,674
Cash flows provided by investing activities:	'		'
Purchases of property and equipment	-79		'
Purchases of marketable securities	-1,499		-4,096
Maturities of marketable securities	2,500		9,700
Net cash provided by investing activities	922		5,604
Cash flows provided by financing activities:	'		'
Proceeds from issuance of common stock, net	379		260
Net cash provided by financing activities	379		260
Net increase (decrease) in cash and cash equivalents	-4,013		2,190
Cash and cash equivalents at beginning of the period	48,588	[1]	49,355
Cash and cash equivalents at end of the period	$44,575		$51,545
[1]	Derived from the Company’s audited financial statements as of December 31, 2013, included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.

General

General	6 Months Ended
	Jun. 30, 2014
General [Abstract]	'
General	'
	Note 1.  General
	We are a biopharmaceutical company that develops novel drugs. Our lead drug candidate, REMOXY® (oxycodone) Extended-Release Capsules CII, is an extended-release oral formulation of oxycodone for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. We designed REMOXY to discourage common methods of tampering and misuse. REMOXY is being developed pursuant to the collaboration agreement and license agreement, or the Pfizer Agreements, between us and King Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc., or Pfizer.
	In the course of our development activities, we have sustained cumulative operating losses. There are no assurances that additional financing will be available on favorable terms, or at all.
	We have prepared the accompanying unaudited condensed financial statements of Pain Therapeutics, Inc. in accordance with generally accepted accounting principles for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for any other interim period or for the year 2014.  For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2013.
	We have evaluated subsequent events through the date of filing this Form 10-Q.

Significant_Accounting_Policie

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Significant Accounting Policies [Abstract]	'
Significant Accounting Policies	'
	Note 2.  Significant Accounting Policies
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. Actual results could differ from those estimates.
	Revenue Recognition
	We recognize revenue when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured. Program fee revenue in 2013 was derived from upfront payments under the Pfizer Agreements. Through the end of 2013, these payments were recognized from receipt over our estimate of the development period for product candidates under the Pfizer Agreements. In October 2013, we and Pfizer amended the Pfizer Agreements to focus on REMOXY and, as a result of the amendment, we recognized all then-remaining deferred program fee revenue as program fee revenue.
	Cash, Cash Equivalents and Concentration of Credit Risk
	We consider all highly liquid financial instruments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents consist of cash maintained at one financial institution and in money market funds. We believe the financial risks associated with these instruments are minimal. We have not experienced material losses from our investments in these securities.
	Marketable Securities and Fair Value Measurements
	We invest in interest bearing marketable securities, generally consisting of corporate and government securities. We may elect to sell these investments before they mature. Therefore, we hold these investments as “available for sale” and include these investments in our balance sheets as current assets, even though the contractual maturity of a particular investment may be beyond one year. We report our marketable securities at fair value, which may include unrealized gains and losses. Our unrealized gains and losses on investments are recorded as a separate component of stockholders’ equity as accumulated other comprehensive income or loss. We recognize all realized gains and losses on our marketable securities on a specific identification basis in interest income in our Statements of Operations. We report changes in net unrealized gains or losses on marketable securities in our Statements of Comprehensive Income. Our marketable securities are maintained at one financial institution and are governed by our investment policy as approved by our Board of Directors.
	To date we have not recorded any impairment charges on marketable securities related to other-than-temporary declines in market value. We would recognize an impairment charge when the decline in the estimated fair value of a marketable security below the amortized cost is determined to be other-than-temporary. We consider various factors in determining whether to recognize an impairment charge, including any adverse changes in the investees’ financial condition, how long the fair value has been below the amortized cost and whether it is more likely than not that we would elect to or be required to sell the marketable security before its anticipated recovery.
	We measure our cash equivalents and marketable securities at fair value on a recurring basis. We use significant observable inputs where there are identical or comparable assets in the market to use in establishing our fair value measurements, including but not limited to benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We consider these inputs to be Level 2 inputs. Generally, the types of instruments we invest in are not traded on a market such as the NASDAQ Global Market, which we would consider to be Level 1 inputs. We do not have any investments that would require inputs considered to be Level 3. We use the bid price to establish fair value where a bid price is available.
	Stock-based Compensation
	We recognize expense for the fair value of all share-based payments, including grants of employee stock options and other share based awards, in our Statements of Operations. For stock options, we use the Black-Scholes option valuation model and the single-option award approach and straight-line attribution method. Using this approach, the compensation cost is amortized on a straight-line basis over the vesting period of each respective stock option, generally four years. We estimate forfeitures and adjust this estimate periodically based on the extent to which future actual forfeitures differ, or are expected to differ, from such estimates.
	We have granted share-based awards that vest upon achievement of certain performance criteria, or Performance Awards. The value of these awards is the product of the number of shares of our common stock to be issued under the award multiplied by the fair market value of a share of our common stock on the date of grant. These awards include future performance criteria. We estimate an implicit service period for achieving these performance criteria. Performance Awards vest and common stock is issued on achieving performance criteria. We recognize stock-based compensation expense for Performance Awards when we conclude that achieving performance criteria is probable. We periodically review and update as appropriate our estimates of the implicit service periods and the likelihood of achieving the performance criteria.
	Net Loss per Share
	We compute basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. We compute diluted net loss per share on the basis of the weighted-average number of common shares outstanding plus dilutive potential common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding stock options and Performance Awards.
	The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands except per share data):
		Three months ended				Six months ended
		June 30,				June 30,
		2014		2013		2014		2013
	Numerator:
	Net loss	$	-3,246	$	-301	$	-6,695	$	-709
	Denominator:
	Weighted-average shares used in computing net loss per share, basic and diluted		45,247		44,999		45,187		44,966
	Net loss per share, basic and diluted	$	-0.07	$	-0.01	$	-0.15	$	-0.02
	Net income (loss) per share - Diluted
	We excluded weighted options outstanding to purchase common stock of 5.5 million for the second quarter of 2014,  14.7 million for the second quarter of 2013,  5.0 million for the first half of 2014 and 14.6 million from the first half of 2013 from the calculation of diluted net loss per share because the effect of including these shares in this calculation would be anti-dilutive.
	Income Taxes
	We make estimates and judgments in determining the need for a provision for income taxes, including the estimation of our taxable income or loss for each full fiscal year. We have accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. We are uncertain about the timing and amount of any future earnings. Accordingly, we offset these deferred tax assets with a valuation allowance. We may in the future determine that certain deferred tax assets will likely be realized, in which case we will reduce our valuation allowance in the period in which such determination is made. If the valuation allowance is reduced, we may recognize a benefit from income taxes in our statement of operations in that period. We classify interest recognized pursuant to our deferred tax assets as interest expense, when appropriate.

Cash_Cash_Equivalents_And_Mark

Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value	6 Months Ended
	Jun. 30, 2014
Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value [Abstract]	'
Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value	'
	Note 3.  Cash, Cash Equivalents and Marketable Securities and Assets Measured at Fair Value
	Our cash, cash equivalents and marketable securities are as follows (in thousands):
			Cash, Cash Equivalents and Marketable Securities
			Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value		Accrued Interest		Total Value
		30-Jun-14
		Cash and cash equivalents	$	44,575	$	—	$	—	$	44,575	$	—	$	44,575
		Commercial paper		250		—		—		250		—		250
			$	44,825	$	—	$	—	$	44,825	$	—	$	44,825
		Reported as:
		Cash and cash equivalents	$	44,575	$	—	$	—	$	44,575	$	—	$	44,575
		Marketable securities		250		—		—		250		—		250
			$	44,825	$	—	$	—	$	44,825	$	—	$	44,825
		Maturities:
		Matures in one year or less	$	44,825	$	—	$	—	$	44,825	$	—	$	44,825
		Matures one to three years		—		—		—		—		—		—
			$	44,825	$	—	$	—	$	44,825	$	—	$	44,825
		31-Dec-13
		Cash and cash equivalents	$	48,587	$	1	$	—	$	48,588	$	—	$	48,588
		Corporate securities		1,250		—		—		1,250		—		1,250
			$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
		Reported as:
		Cash and cash equivalents	$	48,587	$	1	$	—	$	48,588	$	—	$	48,588
		Marketable securities		1,250		—		—		1,250		—		1,250
			$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
		Maturities:
		Matures in one year or less	$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
		Matures one to three years		—		—		—		—		—		—
			$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
	We did not realize any gains or losses on our investments in marketable securities during the first six months of 2014 or 2013. To date we have not recorded any impairment charges on marketable securities related to other-than-temporary declines in market value.
	Our assets measured at fair value on a recurring basis are as follows (in thousands):
			Level 1		Level 2		Level 3		Total
		30-Jun-14
		Cash and money market fund	$	44,575	$	—	$	—	$	44,575
		Commercial paper		—		250		—		250
			$	44,575	$	250	$	—	$	44,825
		31-Dec-13
		Cash and money market fund	$	48,588	$	—	$	—	$	48,588
		Corporate securities		—		1,250		—		1,250
			$	48,588	$	1,250	$	—	$	49,838

Option_And_Performance_Award_A

Option And Performance Award Activity And Non-Cash Stock-Based Compensation Expense	6 Months Ended
	Jun. 30, 2014
Option And Performance Award Activity And Non-Cash Stock-Based Compensation Expense [Abstract]	'
Option And Performance Award Activity And Non-Cash Stock-Based Compensation Expense	'
	Note 4.  Option and Performance Award Activity and Non-Cash Stock-Based Compensation Expense
	During the first half of 2014, 1,785,000 stock options and 375,000 Performance Awards were granted, 381,151 options were exercised and 738,664 Performance Awards were cancelled, all pursuant to the 2008 Equity Incentive Plan.
	Our non-cash stock-based compensation expenses are as follows (in thousands):
		Three months ended				Six months ended
		June 30,				June 30,
		2014		2013		2014		2013
	Research and development	$	388	$	337	$	736	$	641
	General and administrative		496		475		931		850
		$	884	$	812	$	1,667	$	1,491

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Taxes [Abstract]	'
Income Taxes	'
	Note 5.  Income Taxes
	We did not provide for income taxes in 2014 because we have projected a net loss for the full year 2014.

Commitments

Commitments	6 Months Ended
	Jun. 30, 2014
Commitments [Abstract]	'
Commitments	'
	Note 6.  Commitments
	We conduct our product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. We have contractual arrangements with these organizations that are cancelable. Our obligations under these contracts are largely based on services performed.
	We have a non-cancelable operating lease for approximately 6,000 square feet of office space in Austin, TX that expires in December 2017.  Minimum lease payments are as follows (in thousands):
		2014		2015		2016		2017		Total
	Minimum lease payments	$	117	$	143	$	146	$	147	$	553

Legal_Proceedings

Legal Proceedings	6 Months Ended
	Jun. 30, 2014
Legal Proceedings [Abstract]	'
Legal Proceedings	'
	Note 7.  Legal proceedings
	KB Partners I, L.P., Individually and On Behalf of All Others Similarly Situated v. Pain Therapeutics, Inc., Remi Barbier, Nadav Friedmann and Peter S. Roddy.
	On December 2, 2011, a purported class action was filed against us and our executive officers in the U.S. District Court for the Western District of Texas. This complaint alleges, among other things, violations of Section 10(b), Rule 10b-5, and Section 20(a) of the Exchange Act arising out of allegedly untrue or misleading statements of material facts made by us regarding REMOXY’s development and regulatory status during the purported class period, February 3, 2011 through June 23, 2011. The complaint states that monetary damages are being sought, but no amounts are specified. On June 3, 2013, the Court certified a class consisting of all purchasers of our common stock and a class period of December 27, 2010 through June 26, 2011.

Recently_Issued_Accounting_Pro

Recently Issued Accounting Pronouncements	6 Months Ended
	Jun. 30, 2014
Recently Issued Accounting Pronouncements [Abstract]	'
Recently Issued Accounting Pronouncements	'
	Note 8.  Recently Issued Accounting Pronouncements
	We reviewed recently issued accounting pronouncements and have adopted or plan to adopt those that are applicable to us. We do not expect the adoption of these pronouncements to have a material impact on our financial position, results of operations or cash flows.

Significant_Accounting_Policie1

Significant Accounting Policies (Policy)	6 Months Ended
	Jun. 30, 2014
Significant Accounting Policies [Abstract]	'
Use Of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. Actual results could differ from those estimates.
Revenue Recognition	'
	Revenue Recognition
	We recognize revenue when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured. Program fee revenue in 2013 was derived from upfront payments under the Pfizer Agreements. Through the end of 2013, these payments were recognized from receipt over our estimate of the development period for product candidates under the Pfizer Agreements. In October 2013, we and Pfizer amended the Pfizer Agreements to focus on REMOXY and, as a result of the amendment, we recognized all then-remaining deferred program fee revenue as program fee revenue.
Cash, Cash Equivalents And Concentration Of Credit Risk	'
	Cash, Cash Equivalents and Concentration of Credit Risk
	We consider all highly liquid financial instruments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents consist of cash maintained at one financial institution and in money market funds. We believe the financial risks associated with these instruments are minimal. We have not experienced material losses from our investments in these securities.
Marketable Securities And Fair Value Measurements	'
	Marketable Securities and Fair Value Measurements
	We invest in interest bearing marketable securities, generally consisting of corporate and government securities. We may elect to sell these investments before they mature. Therefore, we hold these investments as “available for sale” and include these investments in our balance sheets as current assets, even though the contractual maturity of a particular investment may be beyond one year. We report our marketable securities at fair value, which may include unrealized gains and losses. Our unrealized gains and losses on investments are recorded as a separate component of stockholders’ equity as accumulated other comprehensive income or loss. We recognize all realized gains and losses on our marketable securities on a specific identification basis in interest income in our Statements of Operations. We report changes in net unrealized gains or losses on marketable securities in our Statements of Comprehensive Income. Our marketable securities are maintained at one financial institution and are governed by our investment policy as approved by our Board of Directors.
	To date we have not recorded any impairment charges on marketable securities related to other-than-temporary declines in market value. We would recognize an impairment charge when the decline in the estimated fair value of a marketable security below the amortized cost is determined to be other-than-temporary. We consider various factors in determining whether to recognize an impairment charge, including any adverse changes in the investees’ financial condition, how long the fair value has been below the amortized cost and whether it is more likely than not that we would elect to or be required to sell the marketable security before its anticipated recovery.
	We measure our cash equivalents and marketable securities at fair value on a recurring basis. We use significant observable inputs where there are identical or comparable assets in the market to use in establishing our fair value measurements, including but not limited to benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We consider these inputs to be Level 2 inputs. Generally, the types of instruments we invest in are not traded on a market such as the NASDAQ Global Market, which we would consider to be Level 1 inputs. We do not have any investments that would require inputs considered to be Level 3. We use the bid price to establish fair value where a bid price is available.
Stock-Based Compensation	'
	Stock-based Compensation
	We recognize expense for the fair value of all share-based payments, including grants of employee stock options and other share based awards, in our Statements of Operations. For stock options, we use the Black-Scholes option valuation model and the single-option award approach and straight-line attribution method. Using this approach, the compensation cost is amortized on a straight-line basis over the vesting period of each respective stock option, generally four years. We estimate forfeitures and adjust this estimate periodically based on the extent to which future actual forfeitures differ, or are expected to differ, from such estimates.
	We have granted share-based awards that vest upon achievement of certain performance criteria, or Performance Awards. The value of these awards is the product of the number of shares of our common stock to be issued under the award multiplied by the fair market value of a share of our common stock on the date of grant. These awards include future performance criteria. We estimate an implicit service period for achieving these performance criteria. Performance Awards vest and common stock is issued on achieving performance criteria. We recognize stock-based compensation expense for Performance Awards when we conclude that achieving performance criteria is probable. We periodically review and update as appropriate our estimates of the implicit service periods and the likelihood of achieving the performance criteria.
Net Loss Per Share	'
	Net Loss per Share
	We compute basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. We compute diluted net loss per share on the basis of the weighted-average number of common shares outstanding plus dilutive potential common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding stock options and Performance Awards.
	The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands except per share data):
		Three months ended				Six months ended
		June 30,				June 30,
		2014		2013		2014		2013
	Numerator:
	Net loss	$	-3,246	$	-301	$	-6,695	$	-709
	Denominator:
	Weighted-average shares used in computing net loss per share, basic and diluted		45,247		44,999		45,187		44,966
	Net loss per share, basic and diluted	$	-0.07	$	-0.01	$	-0.15	$	-0.02
	Net income (loss) per share - Diluted
	We excluded weighted options outstanding to purchase common stock of 5.5 million for the second quarter of 2014,  14.7 million for the second quarter of 2013,  5.0 million for the first half of 2014 and 14.6 million from the first half of 2013 from the calculation of diluted net loss per share because the effect of including these shares in this calculation would be anti-dilutive.
Income Taxes	'
	Income Taxes
	We make estimates and judgments in determining the need for a provision for income taxes, including the estimation of our taxable income or loss for each full fiscal year. We have accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. We are uncertain about the timing and amount of any future earnings. Accordingly, we offset these deferred tax assets with a valuation allowance. We may in the future determine that certain deferred tax assets will likely be realized, in which case we will reduce our valuation allowance in the period in which such determination is made. If the valuation allowance is reduced, we may recognize a benefit from income taxes in our statement of operations in that period. We classify interest recognized pursuant to our deferred tax assets as interest expense, when appropriate.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Significant Accounting Policies [Abstract]	'
Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share	'
		Three months ended				Six months ended
		June 30,				June 30,
		2014		2013		2014		2013
	Numerator:
	Net loss	$	-3,246	$	-301	$	-6,695	$	-709
	Denominator:
	Weighted-average shares used in computing net loss per share, basic and diluted		45,247		44,999		45,187		44,966
	Net loss per share, basic and diluted	$	-0.07	$	-0.01	$	-0.15	$	-0.02
	Net income (loss) per share - Diluted

Cash_Cash_Equivalents_And_Mark1

Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value (Tables)	6 Months Ended
	Jun. 30, 2014
Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value [Abstract]	'
Cash, Cash Equivalents And Marketable Securities	'
			Cash, Cash Equivalents and Marketable Securities
			Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value		Accrued Interest		Total Value
		30-Jun-14
		Cash and cash equivalents	$	44,575	$	—	$	—	$	44,575	$	—	$	44,575
		Commercial paper		250		—		—		250		—		250
			$	44,825	$	—	$	—	$	44,825	$	—	$	44,825
		Reported as:
		Cash and cash equivalents	$	44,575	$	—	$	—	$	44,575	$	—	$	44,575
		Marketable securities		250		—		—		250		—		250
			$	44,825	$	—	$	—	$	44,825	$	—	$	44,825
		Maturities:
		Matures in one year or less	$	44,825	$	—	$	—	$	44,825	$	—	$	44,825
		Matures one to three years		—		—		—		—		—		—
			$	44,825	$	—	$	—	$	44,825	$	—	$	44,825
		31-Dec-13
		Cash and cash equivalents	$	48,587	$	1	$	—	$	48,588	$	—	$	48,588
		Corporate securities		1,250		—		—		1,250		—		1,250
			$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
		Reported as:
		Cash and cash equivalents	$	48,587	$	1	$	—	$	48,588	$	—	$	48,588
		Marketable securities		1,250		—		—		1,250		—		1,250
			$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
		Maturities:
		Matures in one year or less	$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
		Matures one to three years		—		—		—		—		—		—
			$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
Assets Measured At Fair Value On Recurring Basis	'
			Level 1		Level 2		Level 3		Total
		30-Jun-14
		Cash and money market fund	$	44,575	$	—	$	—	$	44,575
		Commercial paper		—		250		—		250
			$	44,575	$	250	$	—	$	44,825
		31-Dec-13
		Cash and money market fund	$	48,588	$	—	$	—	$	48,588
		Corporate securities		—		1,250		—		1,250
			$	48,588	$	1,250	$	—	$	49,838

Option_And_Performance_Award_A1

Option And Performance Award Activity And Non-Cash Stock-Based Compensation Expense (Tables)	6 Months Ended
	Jun. 30, 2014
Option And Performance Award Activity And Non-Cash Stock-Based Compensation Expense [Abstract]	'
Non-Cash Stock-Based Compensation Expense	'
		Three months ended				Six months ended
		June 30,				June 30,
		2014		2013		2014		2013
	Research and development	$	388	$	337	$	736	$	641
	General and administrative		496		475		931		850
		$	884	$	812	$	1,667	$	1,491

Commitments_Tables

Commitments (Tables)	6 Months Ended
	Jun. 30, 2014
Commitments [Abstract]	'
Future Minimum Lease Payments	'
		2014		2015		2016		2017		Total
	Minimum lease payments	$	117	$	143	$	146	$	147	$	553

Significant_Accounting_Policie3

Significant Accounting Policies (Narrative) (Details)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
			item
Significant Accounting Policies [Abstract]	'	'	'	'
Contractual maturity of a particular investment	'	'	'1 year	'
Number of financial institutions	'	'	1	'
Vesting period of stock options	'	'	'4 years	'
Anti-dilutive shares excluded from computation of diluted net loss per share	5.5	14.7	5	14.6

Significant_Accounting_Policie4

Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Numerator:	'	'	'	'
Net loss	($3,246)	($301)	($6,695)	($709)
Denominator:	'	'	'	'
Weighted-average shares used in computing net loss per share, basic and diluted	45,247	44,999	45,187	44,966
Net loss per share, basic and diluted	($0.07)	($0.01)	($0.15)	($0.02)

Cash_Cash_Equivalents_And_Mark2

Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value (Cash, Cash Equivalents And Marketable Securities) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013		Jun. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'		'	'
Cash and cash equivalents	$44,575	$48,588	[1]	$51,545	$49,355
Cash and cash equivalents, Short Term Investment, Amortized Cost	44,825	49,837		'	'
Cash and cash equivalents, Short Term Investment Unrealized Gains	'	1		'	'
Cash and cash equivalents, Short Term Investment Unrealized Losses	'	'		'	'
Accrued Interest	'	'		'	'
Estimated Fair Value, Marketable securities	250	1,250	[1]	'	'
Cash and cash equivalents, Short Term Investment, Fair Value	44,825	49,838		'	'
Marketable Securities [Member]	'	'		'	'
Schedule of Available-for-sale Securities [Line Items]	'	'		'	'
Available-for-sale securities, Amortized Cost Basis	250	1,250		'	'
Available-for-sale securities, Gross Unrealized Losses	'	'		'	'
Accrued Interest	'	'		'	'
Estimated Fair Value, Marketable securities	250	1,250		'	'
Cash And Cash Equivalents [Member]	'	'		'	'
Schedule of Available-for-sale Securities [Line Items]	'	'		'	'
Cash and cash equivalents	44,575	48,587		'	'
Available-for-sale securities, Gross Unrealized Gains	'	1		'	'
Available-for-sale securities, Gross Unrealized Losses	'	'		'	'
Accrued Interest	'	'		'	'
Cash and cash equivalents, Fair Value	44,575	48,588		'	'
Commercial Paper [Member]	'	'		'	'
Schedule of Available-for-sale Securities [Line Items]	'	'		'	'
Available-for-sale securities, Amortized Cost Basis	250	'		'	'
Available-for-sale securities, Gross Unrealized Losses	'	'		'	'
Accrued Interest	'	'		'	'
Estimated Fair Value, Marketable securities	250	'		'	'
Corporate Securities [Member]	'	'		'	'
Schedule of Available-for-sale Securities [Line Items]	'	'		'	'
Available-for-sale securities, Amortized Cost Basis	'	1,250		'	'
Available-for-sale securities, Gross Unrealized Losses	'	'		'	'
Accrued Interest	'	'		'	'
Estimated Fair Value, Marketable securities	'	1,250		'	'
Cash And Cash Equivalents, Reported Value [Member]	'	'		'	'
Schedule of Available-for-sale Securities [Line Items]	'	'		'	'
Cash and cash equivalents	44,575	48,587		'	'
Available-for-sale securities, Gross Unrealized Gains	'	1		'	'
Available-for-sale securities, Gross Unrealized Losses	'	'		'	'
Accrued Interest	'	'		'	'
Cash and cash equivalents, Fair Value	44,575	48,588		'	'
Matures In One Year Or Less [Member]	'	'		'	'
Schedule of Available-for-sale Securities [Line Items]	'	'		'	'
Cash and cash equivalents, Short Term Investment, Amortized Cost	44,825	49,837		'	'
Available-for-sale securities, Gross Unrealized Gains	'	1		'	'
Available-for-sale securities, Gross Unrealized Losses	'	'		'	'
Accrued Interest	'	'		'	'
Cash and cash equivalents, Short Term Investment, Fair Value	44,825	49,838		'	'
Matures One To Three Years [Member]	'	'		'	'
Schedule of Available-for-sale Securities [Line Items]	'	'		'	'
Cash and cash equivalents, Short Term Investment, Amortized Cost	'	'		'	'
Available-for-sale securities, Gross Unrealized Gains	'	'		'	'
Available-for-sale securities, Gross Unrealized Losses	'	'		'	'
Accrued Interest	'	'		'	'
Cash and cash equivalents, Short Term Investment, Fair Value	'	'		'	'
Estimated Fair Value, Fair Value Disclosure [Member]	'	'		'	'
Schedule of Available-for-sale Securities [Line Items]	'	'		'	'
Cash and cash equivalents, Short Term Investment, Fair Value	44,825	49,838		'	'
Estimated Fair Value, Fair Value Disclosure [Member] | Marketable Securities [Member]	'	'		'	'
Schedule of Available-for-sale Securities [Line Items]	'	'		'	'
Estimated Fair Value, Marketable securities	250	1,250		'	'
Estimated Fair Value, Fair Value Disclosure [Member] | Cash And Cash Equivalents [Member]	'	'		'	'
Schedule of Available-for-sale Securities [Line Items]	'	'		'	'
Cash and cash equivalents, Fair Value	44,575	48,588		'	'
Estimated Fair Value, Fair Value Disclosure [Member] | Commercial Paper [Member]	'	'		'	'
Schedule of Available-for-sale Securities [Line Items]	'	'		'	'
Estimated Fair Value, Marketable securities	250	'		'	'
Estimated Fair Value, Fair Value Disclosure [Member] | Corporate Securities [Member]	'	'		'	'
Schedule of Available-for-sale Securities [Line Items]	'	'		'	'
Estimated Fair Value, Marketable securities	'	1,250		'	'
Estimated Fair Value, Fair Value Disclosure [Member] | Cash And Cash Equivalents, Reported Value [Member]	'	'		'	'
Schedule of Available-for-sale Securities [Line Items]	'	'		'	'
Cash and cash equivalents, Fair Value	44,575	48,588		'	'
Estimated Fair Value, Fair Value Disclosure [Member] | Matures In One Year Or Less [Member]	'	'		'	'
Schedule of Available-for-sale Securities [Line Items]	'	'		'	'
Cash and cash equivalents, Short Term Investment, Fair Value	44,825	49,838		'	'
Estimated Fair Value, Fair Value Disclosure [Member] | Matures One To Three Years [Member]	'	'		'	'
Schedule of Available-for-sale Securities [Line Items]	'	'		'	'
Cash and cash equivalents, Short Term Investment, Fair Value	'	'		'	'
[1]	Derived from the Company’s audited financial statements as of December 31, 2013, included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Cash_Cash_Equivalents_And_Mark3

Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value (Assets Measured At Fair Value On Recurring Basis) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets measured at fair value	$44,825	$49,838
Cash And Money Market Fund [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets measured at fair value	44,575	48,588
Commercial Paper [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets measured at fair value	250	'
Corporate Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets measured at fair value	'	1,250
Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets measured at fair value	44,575	48,588
Level 1 [Member] | Cash And Money Market Fund [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets measured at fair value	44,575	48,588
Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets measured at fair value	250	1,250
Level 2 [Member] | Commercial Paper [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets measured at fair value	250	'
Level 2 [Member] | Corporate Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets measured at fair value	'	$1,250

Option_And_Performance_Award_A2

Option And Performance Award Activity And Non-Cash Stock-Based Compensation Expense (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash stock-based compensation expense	$884	$812	$1,667	$1,491
Stock Options [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Number of Options, Granted	'	'	1,785,000	'
Number of Options, Exercised	'	'	381,151	'
Performance Awards [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Number of Options, Granted	'	'	375,000	'
Number of Options, Cancelled	'	'	738,664	'
Research And Development [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash stock-based compensation expense	388	337	736	641
General And Administrative [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash stock-based compensation expense	$496	$475	$931	$850

Commitments_Narrative_Details

Commitments (Narrative) (Details) (Austin, TX [Member])	6 Months Ended
	Jun. 30, 2014
	sqft
Austin, TX [Member]	'
Operating Leased Assets [Line Items]	'
Office space	6,000
Operating lease expiration year	'2017-12

Commitments_Future_Minimum_Lea

Commitments (Future Minimum Lease Payments) (Details) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Contractual Obligation Fiscal Year Maturity Schedule [Abstract]	'
Future minimum lease payments, 2014	$117
Future minimum lease payments, 2015	143
Future minimum lease payments, 2016	146
Future minimum lease payments, 2017	147
Total	$553